Systematic identification of genomic markers of drug sensitivity in cancer cells

Cytoscape: A software Environment for integrated models of biomolecular interaction networks

Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888

Regularization and Variable Selection Via the Elastic Net

Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

A comparison of normalization methods for high density oligonucleotide array data based on variance and bias

Bolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,328

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720

Clustering by Passing Messages Between Data Points

Frey, B. J., & Dueck, D. (2007) · Science · doi:10.1126/science.1136800 · Cited by 6,855

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477

A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087

Approaches to modernize the combination drug development paradigm

Day, D., & Siu, L. L. (2016) · Genome Medicine · doi:10.1186/s13073-016-0369-x · Cited by 94

Lessons Learned from Two Decades of Anticancer Drugs

Liu, Z., Delavan, B., Roberts, R. A., & Tong, W. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.005 · Cited by 95

CPSF3-dependent pre-mRNA processing as a druggable node in AML and Ewing’s sarcoma

Ross, N. T., Lohmann, F., Carbonneau, S., Fazal, A., Weihofen, W. A., Gleim, S., Salcius, M., Sigoillot, F. D., Hénault, M., Carl, S. H., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0424-1 · Cited by 90

Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group

Grignani, G., D’Ambrosio, L., Pignochino, Y., Palmerini, E., Zucchetti, M., Boccone, P., Aliberti, S., Stacchiotti, S., Bertulli, R., Piana, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30438-8 · Cited by 94

RNA Sequencing of the NCI-60: Integration into CellMiner and CellMiner CDB

Reinhold, W. C., Varma, S. R., Sunshine, M., Elloumi, F., Ofori-Atta, K., Lee, S., Trepel, J. B., Meltzer, P. S., Doroshow, J. H., & Pommier, Y. G. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2047 · Cited by 93

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma

Pan, M., Wright, W. C., Chapple, R. H., Zubair, A., Sandhu, M., Batchelder, J. E., Huddle, B. C., Low, J. A., Blankenship, K., Wang, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26640-x · Cited by 93

Turning liabilities into opportunities: Off-target based drug repurposing in cancer

Palve, V. C., Liao, Y., Rix, L. L. R., & Rix, U. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.003 · Cited by 96

Patient-derived cell line, xenograft and organoid models in lung cancer therapy

Huo, K.-G., D’Arcangelo, E., & Tsao, M. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-154 · Cited by 98

Selection of Personalized Patient Therapy through the Use of Knowledge-Based Computational Models That Identify Tumor-Driving Signal Transduction Pathways

Verhaegh, W., van Ooijen, H., de Inda, M. A., Hatzis, P., Versteeg, R., Smid, M., Martens, J. W. M., Foekens, J. A., van de Wiel, P., Clevers, H. C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2515 · Cited by 91

An unbiased metric of antiproliferative drug effect in vitro

Harris, L. A., Frick, P. L., Garbett, S. P., Hardeman, K. N., Paudel, B. B., Lopez, C. F., Quaranta, V., & Tyson, D. R. (2016) · Nature Methods · doi:10.1038/nmeth.3852 · Cited by 92

Precision medicine in pediatric oncology: Lessons learned and next steps

Mody, R. J., Prensner, J. R., Everett, J. N., Parsons, D. W., & Chinnaiyan, A. M. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26288 · Cited by 94

Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer

Weigelt, B., & Downward, J. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00109 · Cited by 94

Discriminating Live and Dead Cells in Dual-Color Mode with a Two-Photon Fluorescent Probe Based on ESIPT Mechanism

Tian, M., Sun, J., Tang, Y., Dong, B., & Lin, W. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b04252 · Cited by 91

Effects of Charged Particles on Human Tumor Cells

Held, K. D., Kawamura, H., Kaminuma, T., Paz, A., Yoshida, Y., Liu, Q., Willers, H., & Takahashi, A. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00023 · Cited by 98

LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT

Kaufman, J. M., Amann, J. M., Park, K., Arasada, R. R., Li, H., Shyr, Y., & Carbone, D. P. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000173 · Cited by 87

Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers

Aguirre, A. J., & Hahn, W. C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031518 · Cited by 90

Lean Big Data integration in systems biology and systems pharmacology

Ma’ayan, A., Rouillard, A. D., Clark, N. R., Wang, Z., Duan, Q., & Kou, Y. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.07.001 · Cited by 90

Efficacy of ATR inhibitors as single agents in Ewing sarcoma

Nieto-Soler, M., Morgado-Palacin, I., Lafarga, V., Lecona, E., Murga, M., Callén, E., Azorín, D., Alonso, J., Lopez-Contreras, A. J., Nussenzweig, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11643 · Cited by 91

Epigenetics in Cancer: A Hematological Perspective

Stahl, M. F., Kohrman, N., Gore, S. D., Kim, T. K., Zeidan, A. M., & Prébet, T. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006193 · Cited by 92

An Evolutionarily Conserved Synthetic Lethal Interaction Network Identifies FEN1 as a Broad-Spectrum Target for Anticancer Therapeutic Development

van Pel, D. M., Barrett, I. J., Shimizu, Y., Sajesh, B. V., Guppy, B. J., Pfeifer, T., McManus, K. J., & Hieter, P. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003254 · Cited by 89

Translational research in oncology—10 years of progress and future prospects

Doroshow, J. H., & Kummar, S. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.158 · Cited by 91

Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches

Hu, X., & Zhang, Z. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.11.003 · Cited by 94

Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab

Bossi, P., Bergamini, C., Siano, M., Rocca, M. C., Sponghini, A. P., Favales, F., Giannoccaro, M., Marchesi, E., Cortelazzi, B., Perrone, F., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2547 · Cited by 88

Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411)

Schafer, E. S., Rau, R. E., Berg, S. L., Liu, X., Minard, C. G., Bishop, A. J. R., Romero, J. C., Hicks, J. M., Nelson, M. D., Voss, S. D., et al. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.28073 · Cited by 89

Tumor-on-a-chip model for advancement of anti-cancer nano drug delivery system

Tian, C., Zheng, S., Liu, X., & Kamei, K. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01552-0 · Cited by 95

Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer

Udyavar, A. R., Hoeksema, M. D., Clark, J. E., Zou, Y., Tang, Z., Li, Z., Li, M., Chen, H., Statnikov, A., Shyr, Y., et al. (2013) · BMC Systems Biology · doi:10.1186/1752-0509-7-s5-s1 · Cited by 89

Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors

Wang, D. Y. Q., Pham, N., Tong, J., Sakashita, S., Allo, G., Kim, L., Yanagawa, N., Raghavan, V., Wei, Y., To, C., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30472 · Cited by 89

The AURORA initiative for metastatic breast cancer

Zardavas, D., Maetens, M., Irrthum, A., Goulioti, T., Engelen, K., Fumagalli, D., Salgado, R., Aftimos, P. G., Saini, K. S., Sotiriou, C. P., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.341 · Cited by 88

Advancing Precision Medicine for Prostate Cancer Through Genomics

Roychowdhury, S., & Chinnaiyan, A. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3662 · Cited by 88

CRISPR-Cas9–based target validation for p53-reactivating model compounds

Wanzel, M., Vischedyk, J. B., Gittler, M. P., Gremke, N., Seiz, J. R., Hefter, M., Noack, M., Savai, R., Mernberger, M., Charles, J. P., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1965 · Cited by 87

Illuminating the noncoding genome in cancer

Zhang, X., & Meyerson, M. M. (2020) · Nature Cancer · doi:10.1038/s43018-020-00114-3 · Cited by 86

Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation

Orth, M. F., Surdez, D., Faehling, T., Ehlers, A. C., Marchetto, A., Grossetête, S., Volckmann, R., Zwijnenburg, D. A., Gerke, J. S., Zaïdi, S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111761 · Cited by 90

Induction of p53‐mediated transcription and apoptosis by exportin‐1 ( XPO 1) inhibition in mantle cell lymphoma

Yoshimura, M., Ishizawa, J., Ruvolo, V. R., Dilip, A., Quintás‐Cardama, A., McDonnell, T. J., Neelapu, S. S., Kwak, L. W., Shacham, S., Kauffman, M. G., et al. (2014) · Cancer Science · doi:10.1111/cas.12430 · Cited by 90

Consistency in drug response profiling

Mpindi, J. P., Yadav, B., Östling, P., Gautam, P., Malani, D., Murumägi, A., Hirasawa, A., Kangaspeska, S., Wennerberg, K., Kallioniemi, O., et al. (2016) · Nature · doi:10.1038/nature20171 · Cited by 85

From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets

Eifert, C., & Powers, S. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3299 · Cited by 90

A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility

Vecchione, L., Gambino, V., Raaijmakers, J. A., Schlicker, A., Fumagalli, A., Russo, M., Villanueva, A., Beerling, E., Bartolini, A., Mollevı́, D. G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.059 · Cited by 87

The potential of organoids in urological cancer research

Wang, S., Gao, D., & Chen, Y. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.65 · Cited by 87

A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities

Narayan, R. S., Molenaar, P., Teng, J., Cornelissen, F. M. G., Roelofs, I., de Menezes, R. X., Dik, R., Lagerweij, T., Broersma, Y., Petersen, N., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16735-2 · Cited by 89

Dual Targeting of EWS-FLI1 Activity and the Associated DNA Damage Response with Trabectedin and SN38 Synergistically Inhibits Ewing Sarcoma Cell Growth

Grohar, P. J., Segars, L. E., Yeung, C. L., Pommier, Y. G., D’Incalci, M., Mendoza, A., & Helman, L. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0901 · Cited by 86

A survey and systematic assessment of computational methods for drug response prediction

Chen, J., & Zhang, L. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz164 · Cited by 86

Minimal genome-wide human CRISPR-Cas9 library

Gonçalves, E., Thomas, M., Behan, F. M., Picco, G., Pacini, C., Allen, F. R., Vinceti, A., Sharma, M., Jackson, D. A., Price, S., et al. (2021) · Genome biology · doi:10.1186/s13059-021-02268-4 · Cited by 87

Mouse models of colorectal cancer as preclinical models

McIntyre, R. E., Buczacki, S. J. A., Arends, M. J., & Adams, D. J. (2015) · BioEssays · doi:10.1002/bies.201500032 · Cited by 86

BRAF and AXL oncogenes drive RIPK3 expression loss in cancer

Najafov, A., Zervantonakis, I. K., Mookhtiar, A. K., Greninger, P., March, R. J., Egan, R. K., Luu, H. S., Stover, D. G., Matulonis, U. A., Benes, C. H., et al. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2005756 · Cited by 89

FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors

Jardim, D. L. F., Wheler, J. J., Hess, K. R., Tsimberidou, A. M., Zinner, R., Jankú, F., Subbiah, V., Naing, A., Piha-Paul, S. A., Westin, S. N., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089388 · Cited by 86

DeepDRK: a deep learning framework for drug repurposing through kernel-based multi-omics integration

Wang, Y., Yang, Y., Chen, S., & Wang, J. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab048 · Cited by 86

Organoids as Models for Neoplastic Transformation

Neal, J. T., & Kuo, C. J. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044249 · Cited by 85

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma

Gill, S. J., Travers, J., Pshenichnaya, I., Kogera, F., Barthorpe, S., Mironenko, T., Richardson, L., Benes, C. H., Stratton, M. R., McDermott, U., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140988 · Cited by 83

ITGA1 is a pre-malignant biomarker that promotes therapy resistance and metastatic potential in pancreatic cancer

Gharibi, A., Kim, S. L., Molnar, J., Brambilla, D., Adamian, Y., Hoover, M. Y., Hong, J., Lin, J., Wolfenden, L., & Kelber, J. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-09946-z · Cited by 84

Microfluidics as an Enabling Technology for Personalized Cancer Therapy

Mathur, L., Ballinger, M., Utharala, R., & Merten, C. A. (2019) · Small · doi:10.1002/smll.201904321 · Cited by 83

Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome

Tsvetkov, P., Mendillo, M. L., Zhao, J., Carette, J. E., Merrill, P. H., Cikes, D., Varadarajan, M., van Diemen, F. R., Penninger, J. M., Goldberg, A. L., et al. (2015) · eLife · doi:10.7554/elife.08467 · Cited by 83

New readers and interpretations of poly(ADP-ribosyl)ation

Kalisch, T., Amé, J., Dantzer, F., & Schreiber, V. (2012) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2012.06.001 · Cited by 83

Predicting tumor response to drugs based on gene-expression biomarkers of sensitivity learned from cancer cell lines

Li, Y., Umbach, D. M., Krahn, J. M., Shats, I., Li, X., & Li, L. (2021) · BMC Genomics · doi:10.1186/s12864-021-07581-7 · Cited by 88

Translational Horizons in the Tumor Microenvironment: Harnessing Breakthroughs and Targeting Cures

Sun, Y. (2015) · Medicinal Research Reviews · doi:10.1002/med.21338 · Cited by 85

Ewing’s sarcoma precursors are highly enriched in embryonic osteochondrogenic progenitors

Tanaka, M., Yamazaki, Y., Kanno, Y., Igarashi, K., Aisaki, K., Kanno, J., & Nakamura, T. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72399 · Cited by 86

Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress

Murai, J., Zhang, H., Pongor, L. S., Tang, S.-W., Jo, U., Moribe, F., Ma, Y., Tomita, M., & Pommier, Y. G. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.02.117 · Cited by 84

Current Status of Management and Outcome for Patients with Ewing Sarcoma

Hesla, A. C., Papakonstantinou, A., & Tsagkozis, P. (2021) · Cancers · doi:10.3390/cancers13061202 · Cited by 86

Overexpression of the Mitochondrial Folate and Glycine–Serine Pathway: A New Determinant of Methotrexate Selectivity in Tumors

Vázquez, A., Tedeschi, P. M., & Bertino, J. R. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-3709 · Cited by 82

Drug Sensitivity Assays of Human Cancer Organoid Cultures

Francies, H. E., Barthorpe, A. S., McLaren-Douglas, A., Barendt, W. J., & Garnett, M. J. (2016) · Methods in molecular biology · doi:10.1007/7651_2016_10 · Cited by 82

Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212

Wagner, J., Kline, C. L. B., Ralff, M. D., Lev, A., Lulla, A. R., Zhou, L., Olson, G. L., Nallaganchu, B. R., Benes, C. H., Allen, J. E., et al. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1325046 · Cited by 82

Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection

Sinha, R., Winer, A., Chevinsky, M. S., Jakubowski, C. D., Chen, Y., Dong, Y., Tickoo, S. K., Reuter, V. E., Russo, P., Coleman, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms15165 · Cited by 86

Targeting chromatin complexes in fusion protein-driven malignancies

Brien, G. L., Stegmaier, K., & Armstrong, S. A. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0132-x · Cited by 84

Mutational signatures are markers of drug sensitivity of cancer cells

Levatić, J., Salvadores, M., Fuster‐Tormo, F., & Supek, F. (2022) · Nature Communications · doi:10.1038/s41467-022-30582-3 · Cited by 79

BRAID: A Unifying Paradigm for the Analysis of Combined Drug Action

Twarog, N. R., Stewart, E. A., Hammill, C. V., & Shelat, A. A. (2016) · Scientific Reports · doi:10.1038/srep25523 · Cited by 81

Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity

Wang, J., Mouradov, D., Wang, X., Jorissen, R. N., Chambers, M., Zimmerman, L. J., Vasaikar, S. V., Love, C. G., Li, S., Lowes, K. N., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.008 · Cited by 79

CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response

Szlachta, K. A., Kuscu, C., Tufan, T., Adair, S. J., Shang, S., Michaels, A. D., Mullen, M. G., Fischer, N. L., Yang, J., Liu, L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06676-2 · Cited by 83

Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions

Alkema, N. G., Wisman, G. B. A., van der Zee, A. G. J., van Vugt, M. A. T. M., & de Jong, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.005 · Cited by 84

Meta-GDBP: a high-level stacked regression model to improve anticancer drug response prediction

Su, R., Liu, X., Xiao, G., & Wei, L. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz022 · Cited by 78

Organoid screening reveals epigenetic vulnerabilities in human colorectal cancer

Toshimitsu, K., Takano, A., Fujii, M., Togasaki, K., Matano, M., Takahashi, S., Kanai∥, T., & Sato, T. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-00984-x · Cited by 84

NAMPT Is the Cellular Target of STF-31-Like Small-Molecule Probes

Adams, D., Ito, D., Rees, M. G., Seashore-Ludlow, B. A., Puyang, X., Ramos, A. H., Cheah, J. H., Clemons, P. A., Warmuth, M., Zhu, P., et al. (2014) · ACS Chemical Biology · doi:10.1021/cb500347p · Cited by 81

Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer

Moser, R. D., Xu, C., Kao, M. C., Annis, J. E., Lerma, L. A., Schaupp, C. M., Gurley, K. E., Jang, I. S., Biktasova, A., Yarbrough, W. G., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2858 · Cited by 80

Toward an integrated map of genetic interactions in cancer cells

Rauscher, B., Heigwer, F., Henkel, L., Hielscher, T., Voloshanenko, O., & Boutros, M. (2018) · Molecular Systems Biology · doi:10.15252/msb.20177656 · Cited by 77

Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force

Bailey, K. M., Cost, C. R., Davis, I. J., Bender, J. G., Grohar, P. J., Houghton, P. J., Isakoff, M. S., Stewart, E. S., Laack, N. N., Yustein, J. T., et al. (2019) · F1000Research · doi:10.12688/f1000research.18139.1 · Cited by 79

Network Analysis of the Focal Adhesion to Invadopodia Transition Identifies a PI3K-PKCα Invasive Signaling Axis

Hoshino, D., Jourquin, J., Emmons, S. W., Miller‐Fleming, T. W., Goldgof, M., Costello, K., Tyson, D. R., Brown, B. T., Lu, Y., Prasad, N. K., et al. (2012) · Science Signaling · doi:10.1126/scisignal.2002964 · Cited by 79

PARP1 Is Overexpressed in Nasopharyngeal Carcinoma and Its Inhibition Enhances Radiotherapy

Chow, J. P. H., Man, W. Y., Mao, M., Chen, H., Cheung, F. M. F., Nicholls, J. M., Tsao, S. W., Lung, M. L., & Poon, R. Y. C. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0010 · Cited by 79

Aiming at the sweet side of cancer: Aberrant glycosylation as possible target for personalized-medicine

Padler‐Karavani, V. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.10.005 · Cited by 79

IntegratedMRF: random forest-based framework for integrating prediction from different data types

Rahman, R., Otridge, J., & Pal, R. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw765 · Cited by 78

Time series modeling of live-cell shape dynamics for image-based phenotypic profiling

Gordonov, S., Hwang, M. K., Wells, A. H., Gertler, F. B., Lauffenburger, D. A., & Bathe, M. (2015) · Integrative Biology · doi:10.1039/c5ib00283d · Cited by 78

TANDEM: a two-stage approach to maximize interpretability of drug response models based on multiple molecular data types

Aben, N., Vis, D. J., Michaut, M., & Wessels, L. F. A. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw449 · Cited by 75

Deep reinforcement learning for personalized treatment recommendation

Liu, M., Shen, X., & Pan, W. (2022) · Statistics in Medicine · doi:10.1002/sim.9491 · Cited by 85

Relating hepatocellular carcinoma tumor samples and cell lines using gene expression data in translational research

Chen, B., Sirota, M., Fan-Minogue, H., Hadley, D., & Butte, A. J. (2015) · BMC Medical Genomics · doi:10.1186/1755-8794-8-s2-s5 · Cited by 80

Label-free drug discovery

Ye, F. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00052 · Cited by 80

Critical parameters in targeted drug development: the pharmacological audit trail

Banerji, U., & Workman, P. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.06.001 · Cited by 78

Drug response consistency in CCLE and CGP

Bouhaddou, M., DiStefano, M. S., Riesel, E. A., Carrasco, E., Holzapfel, H. Y., Jones, D. C., Smith, G. R., Stern, A. D., Somani, S. S., Thompson, T. V., et al. (2016) · Nature · doi:10.1038/nature20580 · Cited by 76

TBK1 Provides Context-Selective Support of the Activated AKT/mTOR Pathway in Lung Cancer

Cooper, J. M., Ou, Y.-H., McMillan, E. A., Vaden, R. M., Zaman, A., Bodemann, B. O., Makkar, G., Posner, B. A., & White, M. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0829 · Cited by 79

The Missing Pieces of Artificial Intelligence in Medicine

Gilvary, C. M., Madhukar, N. S., Elkhader, J. A., & Elemento, O. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.06.001 · Cited by 78

Integrative analysis for identifying joint modular patterns of gene-expression and drug-response data

Chen, J., & Zhang, S. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw059 · Cited by 76

Synthetic lethal interaction between the tumour suppressor STAG2 and its paralog STAG1

Benedetti, L. G., Cereda, M., Monteverde, L., Desai, N., & Ciccarelli, F. D. (2017) · Oncotarget · doi:10.18632/oncotarget.16838 · Cited by 81

Revisiting inconsistency in large pharmacogenomic studies

Safikhani, Z., Freeman, M., Smirnov, P., El-Hachem, N., She, A., Quevedo, R., Goldenberg, A., Birkbak, N. J., Hatzis, C., Shi, L. M., et al. (2016) · F1000Research · doi:10.12688/f1000research.9611.3 · Cited by 106

Towards Structural Systems Pharmacology to Study Complex Diseases and Personalized Medicine

Xie, L., Ge, X., Tan, H., Xie, L., Zhang, Y., Hart, T. D., Yang, X., & Bourne, P. E. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003554 · Cited by 75

Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1

Ren, M., HONG, M., Liu, G., WANG, H., Patel, V. S., Biddinger, P. W., Silva, J., Cowell, J. K., & Hao, Z. (2013) · Oncology Reports · doi:10.3892/or.2013.2386 · Cited by 76

Systems biology–based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma

Huang, L. F., Injac, S. G., Cui, K., Braun, F., Qi, L., Du, Y., Zhang, H., Kogiso, M., Lindsay, H., Zhao, S., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat0150 · Cited by 73

Autoencoder Based Feature Selection Method for Classification of Anticancer Drug Response

Xu, X., Gu, H., Wang, Y., Wang, J., & Qin, P. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00233 · Cited by 75

An ecosystem of cancer cell line factories to support a cancer dependency map

Boehm, J. S., & Golub, T. R. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3967 · Cited by 75

Colorectal Cancer Subtypes: Developmental Origin and Microenvironmental Regulation

Fessler, E., & Medema, J. P. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.07.008 · Cited by 81

TRIM28 multi-domain protein regulates cancer stem cell population in breast tumor development

Czerwińska, P., Shah, P. K., Tomczak, K. J., Klimczak, M., Mazurek, S., Sozańska, B., Biecek, P., Korski, K., Filas, V., Mackiewicz, A. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13273 · Cited by 73

Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers

Hata, A. N., Yeo, A., Faber, A. C., Lifshits, E., Chen, Z., Cheng, K. A., Walton, Z., Sarosiek, K. A., Letai, A., Heist, R. S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3728 · Cited by 74

Logic models to predict continuous outputs based on binary inputs with an application to personalized cancer therapy

Knijnenburg, T. A., Klau, G. W., Iorio, F., Garnett, M. J., McDermott, U., Shmulevich, I., & Wessels, L. F. A. (2016) · Scientific Reports · doi:10.1038/srep36812 · Cited by 74

Large-scale integration of small molecule-induced genome-wide transcriptional responses, Kinome-wide binding affinities and cell-growth inhibition profiles reveal global trends characterizing systems-level drug action

Vidović, D., Koleti, A., & Schürer, S. C. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00342 · Cited by 74

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib

Raspé, E., Coulonval, K., Pita, J. M. G., Paternot, S., Rothé, F., Twyffels, L., Brohée, S., Craciun, L., Larsimont, D., Kruys, V., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607084 · Cited by 76

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950

Cell lines battle cancer

Weinstein, J. N. (2012) · Nature · doi:10.1038/483544a · Cited by 109

Pharmacogenomic profiling of cancer drugs

Aschheim, K. (2012) · Nature Biotechnology · doi:10.1038/nbt.2231 · Cited by 1

Cells line up to be characterized

Kirk, R. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.56 · Cited by 2

Integrative Statistical Inferences for Drug Sensitivity Biomarkers in CancerPreprint

Ullah, E., Shama, S., Muftah, N. A., Thompson, I. R., Rawi, R., Mall, R., & Bensmail, H. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/194670